Do analysts recommend ELAB or BGMS?

Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score PMGC 1 Sell rating(s) 0 Hold rating(s) 0 Buy rating(s) 0 Strong Buy rating(s) 1.00 Cyclacel Pharmaceuticals 1 Sell rating(s) 0 Hold rating(s) 0 Buy rating(s) 0 Strong Buy rating(s) 1.00

Is ELAB or BGMS more profitable?

Cyclacel Pharmaceuticals' return on equity of -51.21% beat PMGC's return on equity. Company Net Margins Return on Equity Return on Assets PMGC N/A -117.82% -70.79% Cyclacel Pharmaceuticals N/A -51.21% -44.00%

Do analysts rate CELZ or ELAB?

Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score Creative Medical Technology 1 Sell rating(s) 1 Hold rating(s) 0 Buy rating(s) 0 Strong Buy rating(s) 1.50 PMGC 1 Sell rating(s) 0 Hold rating(s) 0 Buy rating(s) 0 Strong Buy rating(s) 1.00

Is CELZ or ELAB more profitable?

Creative Medical Technology's return on equity of -88.38% beat PMGC's return on equity. Company Net Margins Return on Equity Return on Assets Creative Medical Technology N/A -88.38% -84.71% PMGC N/A -117.82% -70.79%

Do analysts rate CUPR or ELAB?

Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score Cuprina Holdings (Cayman) 1 Sell rating(s) 0 Hold rating(s) 0 Buy rating(s) 0 Strong Buy rating(s) 1.00 PMGC 1 Sell rating(s) 0 Hold rating(s) 0 Buy rating(s) 0 Strong Buy rating(s) 1.00

Which has better earnings & valuation, CUPR or ELAB?

Cuprina Holdings (Cayman) has higher earnings, but lower revenue than PMGC. Company Gross Revenue Price/Sales Ratio Net Income Earnings Per Share Price/Earnings Ratio Cuprina Holdings (Cayman) $40K 94.76 -$3.63M N/A N/A PMGC $590K 2.23 -$7.75M -$168.62 N/A

Is CUPR or ELAB more profitable?

Cuprina Holdings (Cayman)'s return on equity of 0.00% beat PMGC's return on equity. Company Net Margins Return on Equity Return on Assets Cuprina Holdings (Cayman) N/A N/A N/A PMGC N/A -117.82% -70.79%

Do analysts recommend ALZN or ELAB?

Alzamend Neuro presently has a consensus target price of $28.00, indicating a potential upside of 2,282.98%. Given Alzamend Neuro's stronger consensus rating and higher possible upside, research analysts clearly believe Alzamend Neuro is more favorable than PMGC. Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score Alzamend Neuro 1 Sell rating(s) 0 Hold rating(s) 1 Buy rating(s) 0 Strong Buy rating(s) 2.00 PMGC 1 Sell rating(s) 0 Hold rating(s) 0 Buy rating(s) 0 Strong Buy rating(s) 1.00

Is ALZN or ELAB more profitable?

PMGC's return on equity of -117.82% beat Alzamend Neuro's return on equity. Company Net Margins Return on Equity Return on Assets Alzamend Neuro N/A -177.52% -140.41% PMGC N/A -117.82% -70.79%

Do analysts recommend ELAB or FBLG?

FibroBiologics has a consensus target price of $74.00, suggesting a potential upside of 8,405.75%. Given FibroBiologics' stronger consensus rating and higher probable upside, analysts clearly believe FibroBiologics is more favorable than PMGC. Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score PMGC 1 Sell rating(s) 0 Hold rating(s) 0 Buy rating(s) 0 Strong Buy rating(s) 1.00 FibroBiologics 1 Sell rating(s) 2 Hold rating(s) 1 Buy rating(s) 0 Strong Buy rating(s) 2.00

Is ELAB or FBLG more profitable?

PMGC's return on equity of -117.82% beat FibroBiologics' return on equity. Company Net Margins Return on Equity Return on Assets PMGC N/A -117.82% -70.79% FibroBiologics N/A -767.07% -195.56%

Does the media prefer ELAB or FBLG?

In the previous week, PMGC had 3 more articles in the media than FibroBiologics. MarketBeat recorded 6 mentions for PMGC and 3 mentions for FibroBiologics. FibroBiologics' average media sentiment score of 0.53 beat PMGC's score of 0.48 indicating that FibroBiologics is being referred to more favorably in the news media. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment PMGC 0 Very Positive mention(s) 0 Positive mention(s) 4 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Neutral FibroBiologics 0 Very Positive mention(s) 1 Positive mention(s) 1 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Positive

PMGC (ELAB) Competitors

$1.14 +0.02 (+1.34%)

As of 11:20 AM Eastern

Compare

ELAB vs. BGMS, CELZ, CUPR, ALZN, and FBLG

Should you buy PMGC stock or one of its competitors? MarketBeat compares PMGC with other companies and stocks that may be similar based on industry, sector, market capitalization, business model, investor interest, or shared news coverage. Companies and stocks commonly compared with PMGC include Cyclacel Pharmaceuticals (BGMS), Creative Medical Technology (CELZ), Cuprina Holdings (Cayman) (CUPR), Alzamend Neuro (ALZN), and FibroBiologics (FBLG). These companies are all part of the "pharmaceutical products" industry.

How does PMGC compare to Cyclacel Pharmaceuticals?

PMGC (NASDAQ:ELAB) and Cyclacel Pharmaceuticals (NASDAQ:BGMS) are both small-cap pharmaceutical products companies, but which is the better stock? We will contrast the two businesses based on the strength of their earnings, risk, media sentiment, valuation, institutional ownership, profitability, analyst recommendations and dividends.

In the previous week, PMGC had 4 more articles in the media than Cyclacel Pharmaceuticals. MarketBeat recorded 6 mentions for PMGC and 2 mentions for Cyclacel Pharmaceuticals. Cyclacel Pharmaceuticals' average media sentiment score of 1.44 beat PMGC's score of 0.48 indicating that Cyclacel Pharmaceuticals is being referred to more favorably in the news media.

Company	Overall Sentiment
PMGC	Neutral
Cyclacel Pharmaceuticals	Positive

22.2% of PMGC shares are held by institutional investors. Comparatively, 23.6% of Cyclacel Pharmaceuticals shares are held by institutional investors. 0.0% of PMGC shares are held by insiders. Comparatively, 23.8% of Cyclacel Pharmaceuticals shares are held by insiders. Strong institutional ownership is an indication that large money managers, endowments and hedge funds believe a company will outperform the market over the long term.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
PMGC	1 Sell rating(s)	0 Hold rating(s)	0 Buy rating(s)	0 Strong Buy rating(s)	1.00
Cyclacel Pharmaceuticals	1 Sell rating(s)	0 Hold rating(s)	0 Buy rating(s)	0 Strong Buy rating(s)	1.00

PMGC has a beta of -0.23, indicating that its stock price is 123% less volatile than the broader market. Comparatively, Cyclacel Pharmaceuticals has a beta of -0.38, indicating that its stock price is 138% less volatile than the broader market.

Cyclacel Pharmaceuticals' return on equity of -51.21% beat PMGC's return on equity.

Company	Net Margins	Return on Equity	Return on Assets
PMGC	N/A	-117.82%	-70.79%
Cyclacel Pharmaceuticals	N/A	-51.21%	-44.00%

Cyclacel Pharmaceuticals has higher revenue and earnings than PMGC. Cyclacel Pharmaceuticals is trading at a lower price-to-earnings ratio than PMGC, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
PMGC	$590K	2.23	-$7.75M	-$168.62	N/A
Cyclacel Pharmaceuticals	$750K	6.58	-$3M	-$4.54	N/A

Summary

Cyclacel Pharmaceuticals beats PMGC on 9 of the 12 factors compared between the two stocks.

How does PMGC compare to Creative Medical Technology?

Creative Medical Technology (NASDAQ:CELZ) and PMGC (NASDAQ:ELAB) are both small-cap pharmaceutical products companies, but which is the better investment? We will compare the two companies based on the strength of their analyst recommendations, valuation, profitability, media sentiment, dividends, earnings, institutional ownership and risk.

In the previous week, PMGC had 4 more articles in the media than Creative Medical Technology. MarketBeat recorded 6 mentions for PMGC and 2 mentions for Creative Medical Technology. PMGC's average media sentiment score of 0.48 beat Creative Medical Technology's score of 0.46 indicating that PMGC is being referred to more favorably in the news media.

Company	Overall Sentiment
Creative Medical Technology	Neutral
PMGC	Neutral

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Creative Medical Technology	1 Sell rating(s)	1 Hold rating(s)	0 Buy rating(s)	0 Strong Buy rating(s)	1.50
PMGC	1 Sell rating(s)	0 Hold rating(s)	0 Buy rating(s)	0 Strong Buy rating(s)	1.00

Creative Medical Technology has higher earnings, but lower revenue than PMGC. Creative Medical Technology is trading at a lower price-to-earnings ratio than PMGC, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Creative Medical Technology	$3K	1,321.44	-$5.99M	-$2.14	N/A
PMGC	$590K	2.23	-$7.75M	-$168.62	N/A

1.4% of Creative Medical Technology shares are owned by institutional investors. Comparatively, 22.2% of PMGC shares are owned by institutional investors. 1.7% of Creative Medical Technology shares are owned by insiders. Comparatively, 0.0% of PMGC shares are owned by insiders. Strong institutional ownership is an indication that hedge funds, large money managers and endowments believe a company is poised for long-term growth.

Creative Medical Technology's return on equity of -88.38% beat PMGC's return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Creative Medical Technology	N/A	-88.38%	-84.71%
PMGC	N/A	-117.82%	-70.79%

Creative Medical Technology has a beta of 1.89, indicating that its stock price is 89% more volatile than the broader market. Comparatively, PMGC has a beta of -0.23, indicating that its stock price is 123% less volatile than the broader market.

Summary

Creative Medical Technology beats PMGC on 7 of the 13 factors compared between the two stocks.

How does PMGC compare to Cuprina Holdings (Cayman)?

Cuprina Holdings (Cayman) (NASDAQ:CUPR) and PMGC (NASDAQ:ELAB) are both small-cap pharmaceutical products companies, but which is the better stock? We will contrast the two businesses based on the strength of their valuation, profitability, dividends, analyst recommendations, media sentiment, institutional ownership, earnings and risk.

In the previous week, PMGC had 4 more articles in the media than Cuprina Holdings (Cayman). MarketBeat recorded 6 mentions for PMGC and 2 mentions for Cuprina Holdings (Cayman). Cuprina Holdings (Cayman)'s average media sentiment score of 1.44 beat PMGC's score of 0.48 indicating that Cuprina Holdings (Cayman) is being referred to more favorably in the media.

Company	Overall Sentiment
Cuprina Holdings (Cayman)	Positive
PMGC	Neutral

Cuprina Holdings (Cayman)'s return on equity of 0.00% beat PMGC's return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Cuprina Holdings (Cayman)	N/A	N/A	N/A
PMGC	N/A	-117.82%	-70.79%

22.2% of PMGC shares are owned by institutional investors. 0.0% of PMGC shares are owned by company insiders. Strong institutional ownership is an indication that endowments, hedge funds and large money managers believe a stock will outperform the market over the long term.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Cuprina Holdings (Cayman)	1 Sell rating(s)	0 Hold rating(s)	0 Buy rating(s)	0 Strong Buy rating(s)	1.00
PMGC	1 Sell rating(s)	0 Hold rating(s)	0 Buy rating(s)	0 Strong Buy rating(s)	1.00

Cuprina Holdings (Cayman) has higher earnings, but lower revenue than PMGC.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Cuprina Holdings (Cayman)	$40K	94.76	-$3.63M	N/A	N/A
PMGC	$590K	2.23	-$7.75M	-$168.62	N/A

Cuprina Holdings (Cayman) has a beta of -1.1, indicating that its share price is 210% less volatile than the broader market. Comparatively, PMGC has a beta of -0.23, indicating that its share price is 123% less volatile than the broader market.

Summary

Cuprina Holdings (Cayman) and PMGC tied by winning 5 of the 10 factors compared between the two stocks.

How does PMGC compare to Alzamend Neuro?

Alzamend Neuro (NASDAQ:ALZN) and PMGC (NASDAQ:ELAB) are both small-cap pharmaceutical products companies, but which is the better investment? We will compare the two companies based on the strength of their profitability, valuation, earnings, dividends, institutional ownership, risk, media sentiment and analyst recommendations.

In the previous week, PMGC had 5 more articles in the media than Alzamend Neuro. MarketBeat recorded 6 mentions for PMGC and 1 mentions for Alzamend Neuro. Alzamend Neuro's average media sentiment score of 1.87 beat PMGC's score of 0.48 indicating that Alzamend Neuro is being referred to more favorably in the media.

Company	Overall Sentiment
Alzamend Neuro	Very Positive
PMGC	Neutral

PMGC's return on equity of -117.82% beat Alzamend Neuro's return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Alzamend Neuro	N/A	-177.52%	-140.41%
PMGC	N/A	-117.82%	-70.79%

Alzamend Neuro presently has a consensus target price of $28.00, indicating a potential upside of 2,282.98%. Given Alzamend Neuro's stronger consensus rating and higher possible upside, research analysts clearly believe Alzamend Neuro is more favorable than PMGC.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Alzamend Neuro	1 Sell rating(s)	0 Hold rating(s)	1 Buy rating(s)	0 Strong Buy rating(s)	2.00
PMGC	1 Sell rating(s)	0 Hold rating(s)	0 Buy rating(s)	0 Strong Buy rating(s)	1.00

Alzamend Neuro has higher earnings, but lower revenue than PMGC. Alzamend Neuro is trading at a lower price-to-earnings ratio than PMGC, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Alzamend Neuro	N/A	N/A	-$4.51M	-$2.16	N/A
PMGC	$590K	2.23	-$7.75M	-$168.62	N/A

Alzamend Neuro has a beta of 0.14, suggesting that its stock price is 86% less volatile than the broader market. Comparatively, PMGC has a beta of -0.23, suggesting that its stock price is 123% less volatile than the broader market.

49.6% of Alzamend Neuro shares are held by institutional investors. Comparatively, 22.2% of PMGC shares are held by institutional investors. 1.4% of Alzamend Neuro shares are held by insiders. Comparatively, 0.0% of PMGC shares are held by insiders. Strong institutional ownership is an indication that endowments, large money managers and hedge funds believe a stock will outperform the market over the long term.

Summary

Alzamend Neuro beats PMGC on 9 of the 14 factors compared between the two stocks.

How does PMGC compare to FibroBiologics?

PMGC (NASDAQ:ELAB) and FibroBiologics (NASDAQ:FBLG) are both small-cap pharmaceutical products companies, but which is the superior stock? We will contrast the two companies based on the strength of their media sentiment, risk, analyst recommendations, dividends, institutional ownership, valuation, earnings and profitability.

FibroBiologics has a consensus target price of $74.00, suggesting a potential upside of 8,405.75%. Given FibroBiologics' stronger consensus rating and higher probable upside, analysts clearly believe FibroBiologics is more favorable than PMGC.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
PMGC	1 Sell rating(s)	0 Hold rating(s)	0 Buy rating(s)	0 Strong Buy rating(s)	1.00
FibroBiologics	1 Sell rating(s)	2 Hold rating(s)	1 Buy rating(s)	0 Strong Buy rating(s)	2.00

PMGC has a beta of -0.23, suggesting that its share price is 123% less volatile than the broader market. Comparatively, FibroBiologics has a beta of 1.14, suggesting that its share price is 14% more volatile than the broader market.

PMGC's return on equity of -117.82% beat FibroBiologics' return on equity.

Company	Net Margins	Return on Equity	Return on Assets
PMGC	N/A	-117.82%	-70.79%
FibroBiologics	N/A	-767.07%	-195.56%

22.2% of PMGC shares are held by institutional investors. 0.0% of PMGC shares are held by company insiders. Comparatively, 9.3% of FibroBiologics shares are held by company insiders. Strong institutional ownership is an indication that large money managers, endowments and hedge funds believe a company is poised for long-term growth.

PMGC has higher revenue and earnings than FibroBiologics. FibroBiologics is trading at a lower price-to-earnings ratio than PMGC, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
PMGC	$590K	2.23	-$7.75M	-$168.62	N/A
FibroBiologics	N/A	N/A	-$18.65M	-$6.93	N/A

In the previous week, PMGC had 3 more articles in the media than FibroBiologics. MarketBeat recorded 6 mentions for PMGC and 3 mentions for FibroBiologics. FibroBiologics' average media sentiment score of 0.53 beat PMGC's score of 0.48 indicating that FibroBiologics is being referred to more favorably in the news media.

Company	Very Positive	Positive	Neutral	Negative	Very Negative	Overall Sentiment
PMGC	0 Very Positive mention(s)	0 Positive mention(s)	4 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Neutral
FibroBiologics	0 Very Positive mention(s)	1 Positive mention(s)	1 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Positive

Summary

PMGC and FibroBiologics tied by winning 7 of the 14 factors compared between the two stocks.

Get PMGC News Delivered to You Automatically

Subscribe Now

SMS is currently available in Australia, Belgium, Canada, France, Germany, Ireland, Italy, New Zealand, the Netherlands, Singapore, South Africa, Spain, Switzerland, the United Kingdom, and the United States. By entering your phone number and clicking the sign-up button, you agree to receive periodic text messages from MarketBeat at the phone number you submitted, including texts that may be sent using an automatic telephone dialing system. Message and data rates may apply. Message frequency will vary. Messages will consist of stock alerts, news stories, and partner advertisements/offers. Consent is not a condition of the purchase of any goods or services. Text HELP for help/customer support. Unsubscribe at any time by replying "STOP" to any text message that you receive from MarketBeat or by visiting our mailing preferences page. Read our full terms of service and privacy policy.

New MarketBeat Followers Over Time

This chart shows the number of new MarketBeat users adding ELAB and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period.

Media Sentiment Over Time

This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.

ELAB vs. The Competition

Export

Metric	PMGC	DIVERSIFIED OPS Industry	Multi-Sector Sector	NASDAQ Exchange
Market Cap	$1.32M	$17.30B	$16.31B	$12.59B
Dividend Yield	N/A	4.71%	4.39%	8.42%
P/E Ratio	-0.01	29.73	25.49	24.43
Price / Sales	2.23	4.70	4.08	91.44
Price / Cash	N/A	49.47	47.29	59.36
Price / Book	0.01	4.40	3.96	6.33
Net Income	-$7.75M	$910.50M	$921.41M	$331.13M
7 Day Performance	7.08%	-2.46%	-2.14%	0.39%
1 Month Performance	-22.26%	-10.11%	-8.80%	-0.53%
1 Year Performance	-99.41%	5.72%	4.37%	20.45%

PMGC Competitors List

Export

Company	MarketRank	Share Price	Analysts' Price Target	1Y Price Performance	Market Cap	Revenue	P/E Ratio	Employee Count	Indicator(s)
ELAB PMGC	0.863 of 5 stars	$1.14 +1.3%	N/A	-99.5%	$1.32M	$590K	N/A	18	Short Interest Decrease Gap Down
BGMS Cyclacel Pharmaceuticals	1.4222 of 5 stars	$0.87 -1.5%	N/A	N/A	$4.80M	$750K	N/A	14	Short Interest Decrease
CELZ Creative Medical Technology	0.5588 of 5 stars	$1.00 -8.3%	N/A	-68.1%	$4.74M	$3K	N/A	5	Short Interest Increase Gap Down
CUPR Cuprina Holdings (Cayman)	1.092 of 5 stars	$5.09 -11.3%	N/A	N/A	$4.68M	$40K	N/A	14	Positive News Short Interest Decrease
ALZN Alzamend Neuro	2.7863 of 5 stars	$1.15 +0.9%	$28.00 +2,334.8%	-61.7%	$4.37M	N/A	N/A	4	Gap Down

Related Companies and Tools

Related Companies

Top 10 Stock Comparisons

This page (NASDAQ:ELAB) was last updated on 7/15/2026 by MarketBeat.com Staff.

From Our Partners

Unlock superior investment research and tools.

Get MarketBeat All Access

In-depth profiles and analysis for 20,000 public companies.
Real-time analyst ratings, insider transactions, earnings data, and more.
Our daily ratings and market update email newsletter.

Sign In
Create Account

Your Email Address:

Your Password:

Forgot your password?

Your Email Address:

Choose a Password:

By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.

PMGC (ELAB) Competitors

ELAB vs. BGMS, CELZ, CUPR, ALZN, and FBLG

How does PMGC compare to Cyclacel Pharmaceuticals?

Summary

How does PMGC compare to Creative Medical Technology?

Summary

How does PMGC compare to Cuprina Holdings (Cayman)?

Summary

How does PMGC compare to Alzamend Neuro?

Summary

How does PMGC compare to FibroBiologics?

Summary

New MarketBeat Followers Over Time

Media Sentiment Over Time

ELAB vs. The Competition

PMGC Competitors List

Related Companies and Tools

Best-in-Class Portfolio Monitoring

Stock Ideas and Recommendations

Advanced Stock Screeners and Research Tools

About MarketBeat

MarketBeat Products

Popular Tools

Financial Calendars

Terms & Info

PMGC (ELAB) Competitors

ELAB vs. BGMS, CELZ, CUPR, ALZN, and FBLG

How does PMGC compare to Cyclacel Pharmaceuticals?

Does the media favor ELAB or BGMS?

Do institutionals & insiders hold more shares of ELAB or BGMS?

Do analysts recommend ELAB or BGMS?

Which has more volatility & risk, ELAB or BGMS?

Is ELAB or BGMS more profitable?

Which has stronger valuation & earnings, ELAB or BGMS?

Summary

How does PMGC compare to Creative Medical Technology?

Does the media prefer CELZ or ELAB?

Do analysts rate CELZ or ELAB?

Which has preferable valuation & earnings, CELZ or ELAB?

Do insiders and institutionals hold more shares of CELZ or ELAB?

Is CELZ or ELAB more profitable?

Which has more risk and volatility, CELZ or ELAB?

Summary

How does PMGC compare to Cuprina Holdings (Cayman)?

Does the media refer more to CUPR or ELAB?

Is CUPR or ELAB more profitable?

Do institutionals and insiders hold more shares of CUPR or ELAB?

Do analysts rate CUPR or ELAB?

Which has better earnings & valuation, CUPR or ELAB?

Which has more volatility & risk, CUPR or ELAB?

Summary

How does PMGC compare to Alzamend Neuro?

Does the media favor ALZN or ELAB?

Is ALZN or ELAB more profitable?

Do analysts recommend ALZN or ELAB?

Which has better valuation & earnings, ALZN or ELAB?

Which has more risk and volatility, ALZN or ELAB?

Do institutionals & insiders believe in ALZN or ELAB?

Summary

How does PMGC compare to FibroBiologics?

Do analysts recommend ELAB or FBLG?

Which has more volatility and risk, ELAB or FBLG?

Is ELAB or FBLG more profitable?

Do institutionals & insiders hold more shares of ELAB or FBLG?

Which has stronger earnings & valuation, ELAB or FBLG?

Does the media prefer ELAB or FBLG?

Summary

New MarketBeat Followers Over Time

Media Sentiment Over Time

ELAB vs. The Competition

PMGC Competitors List

Related Companies and Tools

MarketBeat All Access Features

Best-in-Class Portfolio Monitoring

Stock Ideas and Recommendations

Advanced Stock Screeners and Research Tools